[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Shishido T, Itou T, Ono Y, Arai Y, Miki M: [Adenocarcinoma of the renal pelvis and transitional cell carcinoma of the ureter occurring 11 years after radical cystectomy for bladder cancer: a case report]. Hinyokika Kiyo; 2001 Mar;47(3):187-90
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma of the renal pelvis and transitional cell carcinoma of the ureter occurring 11 years after radical cystectomy for bladder cancer: a case report].
  • We report a case of upper urinary tract carcinoma which recurred 11 years after total cystectomy.
  • Carcinoma in situ was diagnosed pathologically.
  • The pathological diagnosis was transitional cell carcinoma, grade 3, pTis.
  • The right kidney was not visualized on IVP and computed tomography revealed a right renal irregular mass.
  • The pathologic diagnosis was renal pelvic adenocarcinoma and ureteral transitional cell carcinoma.
  • The patient was treated postoperatively with 3 cycles of systemic chemotherapy and radiotherapy.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Transitional Cell / etiology. Cystectomy. Kidney Neoplasms / etiology. Kidney Pelvis. Neoplasms, Second Primary / etiology. Postoperative Complications. Ureteral Neoplasms / etiology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Humans. Male. Middle Aged. Time Factors


2. Yamamoto H, Ueda Y, Maruyama T, Kondou N, Nojima M, Takiuchi H, Mori Y, Shima H, Kubota A: [A case of CA19-9 producing transitional cell carcinoma of the ureter]. Hinyokika Kiyo; 2003 Sep;49(9):543-5
Genetic Alliance. consumer health - Transitional cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of CA19-9 producing transitional cell carcinoma of the ureter].
  • We report a case of CA19-9 producing urothelial carcinoma of the right ureter.
  • Magnetic resonance urography and retrograde ureterography revealed a long irregular filling defect in the right distal ureter.
  • Under the diagnosis of right ureteral tumor, we performed right total nephroureterectomy and pelvic lymphadenectomy.
  • The tumor was histologically diagnosed as grade 1 transitional cell carcinoma and pelvic lymphnodes were positive (pT1N2M0).
  • The serum CA19-9 level was normalized after the operation and successive adjuvant chemotherapy (M-VAC 2 course).
  • [MeSH-major] Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Carcinoma, Transitional Cell / immunology. Ureteral Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14598694.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


3. Sakuma T, Ujike T, Yoshida T, Ohashi H, Kawano K: [Urothelial carcinoma of ureter with neuroendocrine differentiation: a case report]. Hinyokika Kiyo; 2008 Feb;54(2):123-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urothelial carcinoma of ureter with neuroendocrine differentiation: a case report].
  • Urine cytology showed small cell carcinoma (SmCC) cells mixed with urothelial carcinoma (UC) cells.
  • Cystoscopy revealed a bladder tumor around the right ureteral orifice.
  • With laparoscopic nephrectomy/open ureterectomy, distal end (approximately 10 cm) of the right ureter was tumorous and obstructed.
  • The tumor of lower-end of ureter tumor was SmCC, showing neuroendocrine differentiation such as pseudo-rosette, positive Grimelius stain, and chromogranin A/NCAM/synaptophysin immunostaining.
  • Proximal to this tumor, non-invasive UC spread superficially over entire length of the ureter to the renal pelvis.
  • Abrupt transition from invasive SmCC to non-invasive UC was observed in the middle of the ureter.
  • Post-operative adjuvant chemotherapy was discouraged due to senile dementia of the patient.
  • The patient died nine months after the operation because of systemic progression of cancer.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology. Ureteral Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323171.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Fujisawa H, Takagane H, Shimosegawa K, Sakuma T: [Primary malignant lymphoma of the ureter: a case report]. Hinyokika Kiyo; 2004 Oct;50(10):721-4
Genetic Alliance. consumer health - Primary malignant lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant lymphoma of the ureter: a case report].
  • Computed tomography and retrograde pyelography revealed a soft tissue mass in the middle portion of the right ureter.
  • Urine cytology specimen from the right ureter suggested transitional cell carcinoma.
  • Under the diagnosis of right ureteral cancer, we performed right total nephro-ureterectomy, partial cystectomy.
  • The histopathological examination showed non-Hodgkin lymphoma (large B-cell type) of the ureter.
  • Our diagnosis was Clinical Stage IE of the Ann Arbor Classification.
  • The patient received only the first course of systemic chemotherapy (THP-cop), because he suffered severe thrombocytopenia in the course of the chemotherapy.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Ureteral Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15575226.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Matsushita M, Kawasaki Y, Okada Y: [Carcinomatous meningitis from urothelial carcinoma of bladder and ureter: case report]. Nihon Hinyokika Gakkai Zasshi; 2004 Nov;95(7):817-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinomatous meningitis from urothelial carcinoma of bladder and ureter: case report].
  • Carcinomatous meningitis from urothelial carcinoma of the bladder and ureter is rare.
  • A 77-year-old man with invasive bladder cancer and right ureter cancer had been treated with 3 courses M-VAC (methotrexate, vinblastine, epirubicin, cisplatin) chemotherapy.
  • After chemotherapy we performed radical cystectomy and right nephroureterectomy (ileal-neobladder) (TCC, G3, pT3, N0, M0).
  • Cerebrospinal fluid cytology revealed class V (urothelial carcinoma).
  • Patient died 6 days after diagnosis of carcinomatous meningitis.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Meningeal Neoplasms / secondary. Meningitis / etiology. Ureteral Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Nephrectomy. Ureter / surgery. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Meningitis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15624493.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


6. Yoshimura N, Kanda H, Suzuki R, Yamakawa K, Hayashi N, Arima K, Yanagawa M, Kawamura J: [Cyclophosphamide-induced renal pelvic tumor--a case report]. Hinyokika Kiyo; 2000 Mar;46(3):177-80
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of transitional cell carcinoma in the left renal pelvis, which occurred in a 24-year-old man.
  • A left renal pelvic tumor was strongly suspected on computerized tomography and magnetic resonance imaging.
  • Histological diagnosis of the left renal pelvic tumor was transitional cell carcinoma, grade 2, pT1N0M0.
  • This case seems to be the second case of cyclophosphamide-induced upper urothelial carcinoma reported in Japan.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Carcinoma, Transitional Cell / chemically induced. Cyclophosphamide / adverse effects. Immunosuppressive Agents / adverse effects. Kidney Neoplasms / chemically induced. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Humans. Kidney Pelvis. Male. Nephrectomy. Retroperitoneal Neoplasms / drug therapy. Rhabdomyosarcoma / drug therapy. Time Factors. Treatment Outcome. Ureter / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10806575.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 12
  •  go-up   go-down


7. Segawa N, Kotake Y, Noumi H, Uchimoto S, Azuma H, Katsuoka Y, Tsuji M: [Ureteral tumor occurring from remaining stump: a case report]. Hinyokika Kiyo; 2006 Jul;52(7):565-7
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ureteral tumor occurring from remaining stump: a case report].
  • Primary tumor originated from ureteral stump following nephrectomy for benign disease is extremely rare.
  • Cystoscopic examination revealed a ureteral tumor on the residual ureteral orifice.
  • Under the diagnosis of left ureteral stump tumor, which was subsequently enhanced on computer tomographic scan and magnetic resonance imaging, he received partial cystectomy and excision of the left ureteral stump.
  • The histological examination revealed grade 2 to 3 urothelial carcinoma with muscle invasion (pT2).
  • He received no adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Nephrectomy. Postoperative Complications. Ureter / pathology. Ureteral Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910592.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Kirkali Z, Tuzel E: Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol; 2003 Aug;47(2):155-69
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the ureter and renal pelvis.
  • Transitional cell carcinoma (TCC) of ureter and renal pelvis is relatively uncommon.
  • Approximately 20-50% of patients with upper urinary tract (UUT) TCC have bladder cancer at some point on their course, whereas the incidence of UUT TCC after primary bladder cancer is 0.7-4%.
  • Nephroureterectomy with bladder cuff excision has been the mainstay of treatment.
  • Local resection may be appropriate for distal ureteral lesions especially when the disease is low grade and stage.
  • Adjuvant topical therapies appear to be safe but confirmation of any benefits awaits the results of further large studies.
  • More recently, laparoscopic techniques have become a viable alternative to open surgery, but long term cancer control data are lacking.
  • Adjuvant radiotherapy is ineffective, and systemic chemotherapy results in a low complete response rate for patients with metastases.
  • [MeSH-major] Carcinoma, Transitional Cell. Kidney Neoplasms. Ureteral Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Humans. Kidney Pelvis / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / etiology. Urinary Bladder Neoplasms / therapy

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12900009.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 146
  •  go-up   go-down


9. Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W: Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol; 2004 Oct;172(4 Pt 1):1271-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter.
  • PURPOSE: Transitional cell carcinoma of the upper urinary tract is a relatively uncommon malignancy.
  • The role of adjuvant radiation therapy and chemotherapy is not well defined.
  • We retrospectively reviewed the records of 31 patients who underwent surgery followed by adjuvant radiotherapy with or without concurrent chemotherapy to determine overall outcome as well as impact of concurrent chemotherapy administration.
  • MATERIALS AND METHODS: Between 1970 and 1997, 31 patients with nonmetastatic transitional cell carcinoma of the upper urinary tract (renal pelvis in 13, ureter in 15, and renal pelvis and ureter in 3) were treated with radiotherapy following attempted curative resection.
  • The median radiation dose was 46.9 Gy.
  • Nine patients received methotrexate, cisplatin and vinblastine chemotherapy for 2 to 4 cycles, followed by concurrent cisplatin with radiation.
  • Seven patients (23%) experienced locoregional failure with distant metastases developing in all except 1 within 8 months of locoregional failure diagnosis.
  • On univariate analysis patients had improved 5-year actuarial overall and disease specific survival with the administration of concurrent chemotherapy (27% vs 67%, p = 0.01 and 41% vs 76%, p = 0.06, respectively).
  • CONCLUSIONS: Our series suggests that the addition of concurrent cisplatin to adjuvant radiotherapy improves the ultimate outcome in patients with resected, locally advanced upper tract urothelial malignancies.
  • This regimen should be considered in patients with T3/4 and/or node positive upper tract transitional cell carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / radiotherapy. Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiotherapy. Kidney Pelvis. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / radiotherapy
  • [MeSH-minor] Actuarial Analysis. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Neoplasm, Residual / drug therapy. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Outcome and Process Assessment (Health Care). Radiation-Sensitizing Agents / therapeutic use. Radiotherapy, Adjuvant. Survival Rate. Ureter / pathology. Ureter / surgery


10. Raman JD, Scherr DS: Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol; 2007 Aug;4(8):432-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of patients with upper urinary tract transitional cell carcinoma.
  • Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma (TCC).
  • Radical nephroureterectomy with an ipsilateral bladder cuff is the gold-standard therapy for upper-tract cancers.
  • However, less invasive alternatives have a role in the treatment of this disease.
  • Select patients with a normal contralateral kidney who have small, low-grade lesions might also be candidates for endoscopic ablation.
  • Distal ureterectomy is an option for patients with high-grade, invasive, or bulky tumors of the distal ureter not amenable to endoscopic management.
  • In appropriately selected patients, outcomes following distal ureterectomy are similar to that of radical nephroureterectomy.
  • Bladder cancer is a common occurrence following the management of upper-tract TCC.
  • Extrapolating from data on bladder TCC, both regional lymphadenectomy and neoadjuvant chemotherapy regimens are likely to be beneficial for patients with upper-tract TCC, particularly in the setting of bulky disease.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Urologic Neoplasms / diagnosis. Urologic Neoplasms / surgery
  • [MeSH-minor] Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Kidney Pelvis / pathology. Kidney Pelvis / surgery. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673914.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 107
  •  go-up   go-down


11. Murphy DR, Morris NJ: Transitional cell carcinoma of the urethra [correction of ureter] in a patient with buttock pain: a case report. Arch Phys Med Rehabil; 2008 Jan;89(1):150-2
Genetic Alliance. consumer health - Transitional cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the urethra [correction of ureter] in a patient with buttock pain: a case report.
  • This case reports on a patient with an unusual presentation of a rare tumor: urethral transitional cell carcinoma (TCC).
  • Urethral TCC occurs in approximately 0.7% to 4.0% of patients who have had primary bladder cancer.
  • Buttock pain and the absence of hematuria are uncommon with this disorder.
  • The patient was initially suspected to have piriformis syndrome, but when he did not respond as expected to treatment, and because of his history of primary bladder cancer, further evaluation was undertaken and the diagnosis was made.
  • The patient responded well to radiation and chemotherapy.
  • Musculoskeletal physicians should be particularly suspicious of the presence of urethral TCC in a patient with a history of primary bladder cancer who reports low back or buttock pain, particularly if the patient does not respond quickly to treatment.
  • [MeSH-major] Carcinoma, Transitional Cell / complications. Low Back Pain / etiology. Urethral Neoplasms / complications
  • [MeSH-minor] Aged. Buttocks. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Neoplasms, Multiple Primary. Prostatic Neoplasms. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164345.001).
  • [ISSN] 1532-821X
  • [Journal-full-title] Archives of physical medicine and rehabilitation
  • [ISO-abbreviation] Arch Phys Med Rehabil
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Rassweiler J, Tsivian A, Kumar AV, Lymberakis C, Schulze M, Seeman O, Frede T: Oncological safety of laparoscopic surgery for urological malignancy: experience with more than 1,000 operations. J Urol; 2003 Jun;169(6):2072-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 567 procedures were performed in case of histologically proven cancer, whereas 531 represented only staging operations.
  • There were recurrences after nephroureterectomy for transitional cell carcinoma of the ureter in 1 patient, after radical nephrectomy for renal cell carcinoma in 1, growing teratoma after retroperitoneal lymph node dissection in 2, local recurrence of prostate cancer in 3 and after removal of an adrenal metastasis of melanoma in 1.
  • Two port site metastases (0.18% overall, 0.35% of histologically proved cases) occurred, including metastasis of small cell lung carcinoma after adrenalectomy and a residual mass following 2 cycles of chemotherapy after retroperitoneal lymph node dissection.
  • [MeSH-minor] Adrenalectomy. Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Seeding. Nephrectomy. Pelvis. Postoperative Complications. Prostatectomy. Ureter / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12771722.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Freiha F, Srinivas S: Invasive renal pelvis transitional cell carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4694

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive renal pelvis transitional cell carcinoma.
  • : 4694 Background: Upper tract tumors of the renal pelvis and ureter represent a small proportion of patients with transitional cell carcinoma.
  • We report our experience with invasive renal pelvis and proximal ureter transitional cell carcinoma.
  • METHODS: All patients seen at our institution between 1995 and 2003 with renal pelvis and proximal ureter who had adequate follow up were selected.
  • Of the 37 patients, 13 were ineligible (6= distal ureters; 3=non invasive cancers; 1=urethral cancer; 1=co existing lung cancer; 2=no follow up).
  • RESULTS: The median age was 72(47-92), 2/3 of the patients were men; renal pelvis was the primary site in 21, upper ureter in 3; 13 (54%) were smokers; ten patients (42%)had bladder tumors either preceding the renal pelvis tumor or after; six (25%) of the patients had distant metastases; ten (42%) had nodal metastases;The median overall survival was 27 months.
  • In those patients without nodal metastases, the T stage determined prognosis.
  • Adjuvant chemotherapy in this small series did not have an impact on survival.
  • The overall survival of patients with distant metastases in bladder cancer varies from 9 months to 33 months depending on the performance status and visceral metastases.
  • CONCLUSIONS: The median survival of patients with metastatic renal pelvis and upper tract tumors is worse than bladder cancer.
  • Early detection and adjuvant chemotherapy may have an impact and should be studied in larger number of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Hasegawa T, Hasegawa N, Asano K, Ikemoto I, Onodera S, Ohishi Y: [Simultaneously detected double malignancies on a duplicated kidney associated with atrophied counterpart: a case report]. Hinyokika Kiyo; 2001 Nov;47(11):789-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of simultaneous double malignant tumor in the same kidney, associating renal cell carcinoma with renal pelvic transitional cell carcinoma, in a 70 year-old-male was reported.
  • Drip infusion pyelography and multidetector-row computed tomography demonstrated a tumor mass on the upper pole of the left kidney and atrophic right kidney.
  • Systemic chemotherapy with CDDP, MTX and ADR was performed preoperatively.
  • Then, hemi-left nephrectomy underwent with the diagnosis of renal pelvic tumor and renal tumor.
  • The surgical specimen was pathologically diagnosed as transitional cell carcinoma of the renal pelvis and renal cell carcinoma of its upper pole.
  • This is the 32nd case of simultaneous occurrence of renal cell carcinoma and transitional cell carcinoma in the same kidney in the Japanese literature.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Carcinoma, Transitional Cell / pathology. Kidney / abnormalities. Kidney / pathology. Kidney Neoplasms / pathology. Kidney Pelvis. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged. Atrophy. Humans. Male. Ureter / abnormalities

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11771172.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


15. Zhang Q, Fu S, Liu T, Peng L, Huang G, Lu JJ: Adjuvant intraoperative electron radiotherapy and external beam radiotherapy for locally advanced transitional cell carcinoma of the ureter. Urol Oncol; 2009 Jan-Feb;27(1):14-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant intraoperative electron radiotherapy and external beam radiotherapy for locally advanced transitional cell carcinoma of the ureter.
  • OBJECTIVE: Surgery is the mainstay treatment for transitional cell carcinoma (TCC) of the ureter; however, local recurrence remains a common cause of treatment failure for locally advanced disease after surgery, and the benefit of adjuvant radiotherapy has not been completely determined.
  • The objective of this analysis was to evaluate the outcome of postsurgical high dose radiotherapy consisting of intraoperative electron beam radiotherapy (IOERT) and external beam radiotherapy (EBRT) in locally advanced transitional cell carcinoma of the ureter.
  • METHODS: Seventeen patients with pathologically diagnosed TCC of ureter were treated with nephroureterectomy and adjuvant radiation consisted of IOERT and EBRT according to an institutional research protocol.
  • The dose of IOERT ranged between 10 to 20 Gy (median 14 Gy).
  • Conventional EBRT given with the total dose ranged between 36 and 45 Gy (median 42 Gy).
  • Chemotherapy was utilized in 10 of the 17 patients at the discretion of their primary oncologist.
  • CONCLUSION: IOERT and EBRT following surgery produced a 51% local control and 46% overall survival rate for locally advanced TCC of ureter at 5 years of follow-up, with acceptable rates of acute and late toxicity.
  • Adjuvant IOERT appears to permit dose escalation safely in patients who received conventional adjuvant EBRT and chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / radiotherapy. Electrons / therapeutic use. Radiotherapy, Adjuvant / methods. Urethral Neoplasms / radiotherapy. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Medical Oncology / methods. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367127.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Hisamatsu H, Yamashita S: [A case of metastatic lung cancer with cavitation due to urothelial carcinoma]. Hinyokika Kiyo; 2010 May;56(5):269-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic lung cancer with cavitation due to urothelial carcinoma].
  • We report a rare case of lung cancer with cavitation that was caused by metastasis of urothelial carcinoma.
  • Computed tomography revealed a left ureter tumor, which was removed by left nephroureterectomy in October 2003.
  • However, a part of the ureter could not be resected because of the adhesion that had occurred after a previous operation.
  • The patient was diagnosed with sigmoid colon cancer, and she underwent sigmoidectomy and resection of the remaining part of the ureter in August 2004.
  • Subsequently, transurethral resection was performed several times for bladder tumor.
  • The pathological diagnosis in February 2005 was pT2.
  • Cisplatin-based intra-arterial chemotherapy was performed because it was not possible to perform a cystectomy due to the poor performance status.
  • In March 2006, computed tomography of the chest revealed a mass shadow with a cavity in the left lower lung field.
  • This was diagnosed as primary or metastatic lung cancer and was treated by left lower lobectomy in November 2006.
  • On the basis of the pathological findings, we diagnosed the mass as metastatic tumor secondary to the urothelial carcinoma.
  • Despite general chemotherapy, the patient's condition deteriorated, and the patient died 1 year later.
  • [MeSH-major] Carcinoma, Transitional Cell / radiography. Carcinoma, Transitional Cell / secondary. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Ureteral Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Female. Humans. Nephrectomy. Sigmoid Neoplasms / pathology. Tomography, X-Ray Computed. Ureter / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20519925.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Yasuda K, Kawa G, Kinoshita H, Matsuda T: [Port-site metastasis of an upper urinary tract urothelial carcinoma after laparoscopic nephroureterectomy: a case report]. Hinyokika Kiyo; 2009 Mar;55(3):141-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Port-site metastasis of an upper urinary tract urothelial carcinoma after laparoscopic nephroureterectomy: a case report].
  • We report here a case of ureteral cancer in which port-site metastasis was suspected after a nephroureterectomy.
  • The patient was a male in his fifties with a chief complaint of asymptomatic gross hematuria.
  • A tumor was found in his left renal pelvis and ureter by a computed tomographic (CT) scan.
  • The patient was diagnosed with a left upper urinary tract cancer with a clinical stage of T2N0M0.
  • The pathological diagnosis was an urothelial carcinoma, grade 2 > 3, INFbeta, pT3, pV1, pN2.
  • He received two courses of MVAC chemotherapy (methotrexate 50 mg, vinblastine 5 mg, adriamycin 50mg, cisplatin 120 mg) postoperatively.
  • Since retroperitoneal lymph node metastasis was observed three months later on a CT scan, the MVAC chemotherapy was repeated for three courses.
  • Nine months later, a tumor was found in the hypodermic beside the port-site, and a needle biopsy confirmed a metastatic urothelial carcinoma.
  • He received two courses of GP chemotherapy (gemcitabine 4,250 mg, paclitaxel 225 mg).
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Laparoscopy. Neoplasm Seeding. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378825.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


18. Izes JK, Dyer MW, Callum MG, Bankes P, Libertino JA, Caffrey JA: Ca 125 as a marker of tumor activity in advanced urothelial malignancy. J Urol; 2001 Jun;165(6 Pt 1):1908-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ca 125 as a marker of tumor activity in advanced urothelial malignancy.
  • PURPOSE: The discovery of increased CA 125 in a patient with metastatic bladder carcinoma prompted a prospective study to screen those referred for consideration of adjuvant or palliative chemotherapy of advanced urothelial malignancy for high serum CA 125.
  • Although CA 125 is a useful marker of ovarian cancer and, reportedly, is expressed by a few other tumors, to our knowledge no association with transitional cell malignancy of the urothelium has been previously described.
  • A total of 60 patients had lower urinary tract tumors, 6 had renal or ureteral transitional cell carcinoma and 2 had both lesions.
  • Of these patients 21 underwent surgery alone, 40 underwent both surgery and chemotherapy, and 5 were treated by chemotherapy only.
  • There were 2 patients who received no treatment.
  • Periodic serum CA 125 was obtained in cases found to be initially marker positive and with a change in clinical status.
  • In 5 cases marker increases were seen in the absence of measurable progression but the clinical course indicated therapeutic failure.
  • Overall, a 42% decrease in median levels was seen after chemotherapy.
  • CONCLUSIONS: CA 125 appears to be a marker of disease activity in a patient subset with advanced urothelial malignancy.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Carcinoma, Transitional Cell / blood. Urinary Bladder Neoplasms / blood. Urologic Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371879.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


19. Nakamura H, Kuirhara Y, Matsushita K, Sakai A, Yamaguchi T, Nakajima Y: Extrarenal multiorgan metastases of collecting duct carcinoma of the kidney: a case series. J Med Case Rep; 2008;2:304

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrarenal multiorgan metastases of collecting duct carcinoma of the kidney: a case series.
  • INTRODUCTION: Collecting duct carcinoma is a rare type of renal cell carcinoma.
  • CASE PRESENTATION: We present two case reports of multiorgan metastases of collecting duct carcinoma that were autopsy confirmed.
  • Abdominal computed tomography showed enlargement of the right kidney.
  • These lesions were biopsied, resulting in a histological diagnosis of metastatic adenocarcinoma.
  • Transitional cell carcinoma was suspected, which proved to be misdiagnosed and chemotherapy was given accordingly.
  • Autopsy demonstrated the primary tumor to be collecting duct carcinoma, with metastases to lung, liver, spleen, bone marrow, right adrenal gland, and para-aortic lymph node.
  • Computed tomography done while the patient was alive detected lung, liver, and para-aortic lymph node metastases.
  • Antibiotic therapy improved his symptoms and laboratory indicators of inflammation.
  • One year later, he developed backache.
  • Computed tomography revealed a progressively enlarging right renal lesion, multiple liver masses, enlargement of the para-aortic lymph nodes, and multiple osteoblastic and osteoclastic lesions.
  • Chemotherapy was given without effect, and the patient died of cardiac failure 1 year later.
  • Autopsy revealed a primary tumor of collecting duct carcinoma with metastases to the liver, right adrenal gland, right upper ureter, bone marrow, para-aortic and mediastinal lymph nodes, and bone.
  • CONCLUSION: We present the radiological findings of lung, liver, lymph node, and bone metastases in two patients with collecting duct carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1986 Nov;10(11):1131-41 [3542784.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):449-56 [2318486.001]
  • [Cites] J Urol. 2003 Apr;169(4):1287-90 [12629344.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):627-33 [11222193.001]
  • [Cites] Histopathology. 1991 Feb;18(2):115-22 [1707029.001]
  • [Cites] J Urol. 2000 Apr;163(4):1090-5; quiz 1295 [10737472.001]
  • [Cites] Eur J Radiol. 2006 Mar;57(3):453-60 [16266796.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):54-67 [9503506.001]
  • [Cites] J Comput Assist Tomogr. 1996 May-Jun;20(3):399-403 [8626899.001]
  • [Cites] Arch Esp Urol. 2000 Sep;53(7):611-6 [11037654.001]
  • (PMID = 18798981.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2556681
  •  go-up   go-down


20. Bartsch GC, Kuefer R, Gschwend JE, de Petriconi R, Hautmann RE, Volkmer BG: Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series. Eur Urol; 2007 Mar;51(3):690-7; discussion 697-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydronephrosis as a prognostic marker in bladder cancer in a cystectomy-only series.
  • OBJECTIVES: Hydronephrosis in patients with bladder cancer is caused by tumour at the ureteral orifice, secondary ureteral tumours, intramural or extravesical tumour infiltration, or compression of the ureter.
  • This study investigated the prognostic impact of hydronephrosis in bladder cancer.
  • METHODS: A series of 788 patients were treated with radical cystectomy with curative intent for transitional cell carcinoma of the bladder without neoadjuvant/adjuvant radiotherapy/chemotherapy between January 1986 and September 2003.
  • A multivariate analysis with a Cox regression model was performed with respect to potential influencing factors.
  • Forty-three (32.3%) of the 133 hydronephrotic patients had a tumour involving the ureteral orifice.
  • CONCLUSIONS: Hydronephrosis at the time of diagnosis of bladder cancer is associated with a high probability of advanced tumours.
  • [MeSH-major] Carcinoma, Transitional Cell / complications. Carcinoma, Transitional Cell / surgery. Cystectomy. Hydronephrosis / etiology. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2007 Mar;51(3):591-2 [17174022.001]
  • (PMID = 16904815.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


21. Yasuda Y, Tatokoro M, Yokoyama M, Koga F, Saito K, Masuda H, Fujii Y, Kawakami S, Kihara K: [Successful long-term management of hepatic and lymph nodes metastases of ureteral cancer by multimodal treatment including radiofrequency ablation]. Nihon Hinyokika Gakkai Zasshi; 2010 Nov;101(7):758-63
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful long-term management of hepatic and lymph nodes metastases of ureteral cancer by multimodal treatment including radiofrequency ablation].
  • Computed tomography (CT) scan revealed right hydronephrosis and a slightly enhanced invasive tumor in the right lower ureter, providing a diagnosis of ureteral cancer stage cT3NOM0.
  • The patient underwent minimum incision endoscopic nephrouretectomy, and pathological examination of the resected specimen revealed urothelial carcinoma and squamous cell carcinoma with metastases to right obturator lymph nodes (pT3pN2).
  • After three courses of combination chemotherapy consisting of gemcitabine and cisplatin (GC), one tumor completely disappeared and another achieved a partial response.
  • The patient underwent radiofrequency ablation (RFA) for the residual followed by GC chemotherapy.
  • The patient underwent RFA again followed by GC chemotherapy and then all hepatic metastases have not revealed enlargement.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / therapy. Catheter Ablation. Liver Neoplasms / secondary. Neoplasms, Multiple Primary. Quality of Life. Ureteral Neoplasms / pathology. Ureteral Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Lymphatic Metastasis. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21174743.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Ke HL, Wei YC, Yang SF, Li CC, Wu DC, Huang CH, Wu WJ: Overexpression of hypoxia-inducible factor-1alpha predicts an unfavorable outcome in urothelial carcinoma of the upper urinary tract. Int J Urol; 2008 Mar;15(3):200-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of hypoxia-inducible factor-1alpha predicts an unfavorable outcome in urothelial carcinoma of the upper urinary tract.
  • OBJECTIVES: Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that plays an important role in cell hypoxia adaptation.
  • We evaluated the clinical significance of HIF-1alpha expression in urothelial carcinoma (UC) of the upper urinary tract.
  • METHODS: Ninety-eight cases (mean age = 63.5 +/- 11.7, range = 23-84 years) of renal pelvic or ureter UC were included in the present study.
  • Those who had distant metastasis at diagnosis, other cancer, urolithiasis, incomplete clinical information or had received radiotherapy or chemotherapy before surgery were excluded.
  • RESULTS: Positive HIF-1alpha expression was found in 65 (66.3%) of the cancer specimens.
  • No HIF-1alpha expression was found in normal urothelial specimens.
  • Higher HIF-1alpha score (negative vs 3-5 vs 6-7) was a significant predictor for cancer-specific survival (Cox regression hazard ratio = 2.23, P = 0.004), and tumor recurrence (Cox regression hazard ratio = 1.58, P = 0.036).
  • CONCLUSION: Our findings indicate that HIF-1alpha immunostaining may have an important role in predicting prognosis in upper urinary tract urothelial carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / biosynthesis. Kidney Neoplasms / metabolism. Ureteral Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18304212.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


23. Muranaka T, Kunishima Y, Shigyo M, Kato R, Masumori N, Ito N, Tsukamoto T, Takagi Y, Seki M, Toida I: [Surgical site infection by bacillus Calmette-Guerin (BCG) after radical cystectomy, occurring after intravesical bcg therapy: a case report]. Hinyokika Kiyo; 2007 Aug;53(8):581-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical site infection by bacillus Calmette-Guerin (BCG) after radical cystectomy, occurring after intravesical bcg therapy: a case report].
  • A 51-year-old man received 2 courses of intravesical bacillus Calmette-Guerin (BCG) therapy for carcinoma in situ of the bladder.
  • Two years after the therapy, he underwent left radical nephroureterectomy, cystectomy, urethrectomy and construction of an ileal conduit because of left renal pelvic cancer and severe atrophic bladder.
  • The histopathological diagnosis was carcinoma in situ of the left pelvis and ureter, and epithelioid cell granuloma of left kidney, prostate and bladder.
  • After the operation, he developed extensive surgical site infection (SSI) by BCG, the diagnosis of which was delayed.
  • He recovered from the SSI soon after anti-tuberculosis chemotherapy was begun.
  • We discuss the requirements for more prompt diagnosis of SSI by BCG by analysis of this case.
  • [MeSH-major] BCG Vaccine / adverse effects. Carcinoma, Transitional Cell / drug therapy. Cystectomy. Surgical Wound Infection / etiology. Urinary Bladder Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17874552.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


24. Yang YJ, Lim JS, Lee HJ: Enterocolitis related to chemotherapy with gemcitabine and cisplatin in patient with transitional cell carcinoma of ureter. Eur J Cancer Care (Engl); 2009 Nov;18(6):657-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enterocolitis related to chemotherapy with gemcitabine and cisplatin in patient with transitional cell carcinoma of ureter.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Transitional Cell / drug therapy. Enterocolitis / chemically induced. Ureteral Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19686356.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement